e-therapeutics Management
Management criteria checks 4/4
e-therapeutics' CEO is Ahmad Mortazavi, appointed in Oct 2020, has a tenure of 3.58 years. total yearly compensation is £270.00K, comprised of 77% salary and 23% bonuses, including company stock and options. directly owns 8.72% of the company’s shares, worth £4.58M. The average tenure of the management team and the board of directors is 3.3 years and 4.1 years respectively.
Key information
Ahmad Mortazavi
Chief executive officer
UK£270.0k
Total compensation
| CEO salary percentage | 77.0% |
| CEO tenure | 3.6yrs |
| CEO ownership | 8.7% |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.1yrs |
Recent management updates
Recent updates
e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Jan 05
We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Sep 13e-therapeutics (LON:ETX) Is In A Good Position To Deliver On Growth Plans
Mar 27We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Jul 07We're Not Worried About e-therapeutics' (LON:ETX) Cash Burn
Oct 28Have Insiders Been Buying e-therapeutics plc (LON:ETX) Shares?
Mar 21We Think e-therapeutics (LON:ETX) Can Afford To Drive Business Growth
Feb 14Could The e-therapeutics plc (LON:ETX) Ownership Structure Tell Us Something Useful?
Jan 10
Are Insiders Buying e-therapeutics plc (LON:ETX) Stock?
Dec 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jul 31 2023 | n/a | n/a | -UK£10m |
| Apr 30 2023 | n/a | n/a | -UK£9m |
| Jan 31 2023 | UK£270k | UK£208k | -UK£8m |
| Oct 31 2022 | n/a | n/a | -UK£9m |
| Jul 31 2022 | n/a | n/a | -UK£9m |
| Apr 30 2022 | n/a | n/a | -UK£9m |
| Jan 31 2022 | UK£348k | UK£200k | -UK£8m |
| Oct 31 2021 | n/a | n/a | -UK£6m |
| Jul 31 2021 | n/a | n/a | -UK£4m |
| Apr 30 2021 | n/a | n/a | -UK£4m |
| Jan 31 2021 | UK£136k | UK£107k | -UK£4m |
Compensation vs Market: Ahmad's total compensation ($USD338.12K) is about average for companies of similar size in the UK market ($USD347.41K).
Compensation vs Earnings: Ahmad's compensation has been consistent with company performance over the past year.
CEO
Ahmad Mortazavi (52 yo)
3.6yrs
Tenure
UK£270,000
Compensation
Mr. Ahmad Ali Mortazavi serves as Chief Executive Officer at e-Therapeutics plc since October 2020 and had been its an Executive Chairman since February 10, 2020 until March 01, 2021. Mr. Mortazavi served...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.6yrs | UK£270.00k | 8.72% £ 4.6m | |
| CFO, Director of Finance & Operations and Company Secretary | 1.5yrs | no data | no data | |
| Chief Operating & Business Officer | 1.7yrs | no data | no data | |
| Chief Scientific Officer | 9.4yrs | no data | no data | |
| Head of Software Engineering | 3.3yrs | no data | no data | |
| Head of Therapeutic Discovery | 3.3yrs | no data | no data |
3.3yrs
Average Tenure
Experienced Management: ETX's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 4.3yrs | UK£270.00k | 8.72% £ 4.6m | |
| Independent Non-Executive Chairman | 8.6yrs | UK£55.00k | 0.22% £ 116.5k | |
| Independent Non-Executive Director | 4.3yrs | UK£120.00k | 0.086% £ 45.0k | |
| Chair of Scientific Advisory Board | 4yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data | |
| Member of Scientific Advisory Board | 3.7yrs | no data | no data |
4.1yrs
Average Tenure
68yo
Average Age
Experienced Board: ETX's board of directors are considered experienced (4.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/10 12:44 |
| End of Day Share Price | 2024/05/08 00:00 |
| Earnings | 2023/07/31 |
| Annual Earnings | 2023/01/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
e-therapeutics plc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Philip Morrish | Growth Equities & Company Research |
| Paul Cuddon | Numis Securities Ltd. |
| Savvas Neophitou | Panmure Liberum Historic (Panmure Gordon) |